Avasarala J. Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill. dti [Internet]. 2017 Nov. 8 [cited 2024 Nov. 22];11(1). Available from: https://journals.aboutscience.eu/index.php/dti/article/view/1367